Pradax Class Action
TORONTO, April 10, 2013 /CNW/ - Toronto law firm McPhadden Samac Tuovi LLP has commenced a proposed national class action against Boehringer Ingelheim relating to the blood thinner Pradax. The lawsuit is on behalf of all persons throughout Canada who ingested Pradax.
The claim is for damages in the amount of $150,000,000.
Pradax is used to prevent clotting in patients who suffer from atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes). It is also used by patients who have had hip and knee surgery.
There have been reports that Pradax causes excessive bleeding. There is no antidote that can be taken to stop excessive bleeding that might be caused by Pradax. Bleeding caused by the drug that Pradax was intended to replace, Warfarin, can easily be stopped using a simple administration of vitamin K.In the lawsuit, it is the plaintiff's position that patients should have been warned about the lack of an antidote. Claims are also made on behalf of others who say they suffered harm because of Pradax. SOURCE McPhadden Samac Tuovi LLP
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts